Companies › HBIO
HARVARD BIOSCIENCE INC (HBIO)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001123494 · EDGAR filings · Updated 2026-06-12
HARVARD BIOSCIENCE INC (HBIO) has reported institutional ownership of 3.0%, with 33 institutional managers holding positions valued at $6.57M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-06-12 — Insider transaction reported (Form 4)
- 2026-06-11 — Insider transaction reported (Form 4)
- 2026-06-11 — Insider transaction reported (Form 4)
- 2026-06-11 — Insider transaction reported (Form 4)
- 2026-06-11 — Insider transaction reported (Form 4)
- 2026-06-10 — Employee-plan registration (S-8) filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, HARVARD BIOSCIENCE INC has 33 institutional holders and institutional ownership of 3.0%.
Insider activity
Insiders reported 19 transactions (4 buys, 0 sells) across 8 reporting insiders, with a net reported value of $177.4K.
Data flags from SEC filings
Related companies
Lite Strategy Inc (LITS) · DarioHealth Corp (DRIO) · Traws Pharma Inc (TRAW) · Atossa Therapeutics Inc (ATOS) · MEDICUS PHARMA LTD (MDCX) · NERVGEN PHARMA CORP (NGEN)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-12.